Organ |
liver |
Age classes |
adult |
Gender |
M |
phase I metabolism > CYP1A2 > phenacetin O-deethylation > microsomes |
164 pmol/min/mg protein RATIO: 0.7
|
SanverTech., 1999 - Product characterisation form of In Vitro Technologies, SanverTech, 1999.
|
phase I metabolism > CYP2A6 > coumarin 7-hydroxylation > microsomes |
90 pmol/min/mg protein RATIO: 0.05
|
SanverTech., 1999 - Product characterisation form of In Vitro Technologies, SanverTech, 1999.
|
phase I metabolism > CYP2C19 > S-mephenytoin 4-hydroxylation > microsomes |
3 pmol/min/mg protein RATIO: 0.2
|
SanverTech., 1999 - Product characterisation form of In Vitro Technologies, SanverTech, 1999.
|
phase I metabolism > CYP2D6 > dextromethorphan O-demethylation > microsomes |
1084 pmol/min/mg protein RATIO: 8.5
|
SanverTech., 1999 - Product characterisation form of In Vitro Technologies, SanverTech, 1999.
|
phase I metabolism > CYP2E1 > chlorzoxazone 6-hydroxylation > microsomes |
2115 pmol/min/mg protein RATIO: 1.3
|
SanverTech., 1999 - Product characterisation form of In Vitro Technologies, SanverTech, 1999.
|
phase I metabolism > CYP2E1 > ethoxycoumarin O-deethylation > microsomes |
781 pmol/min/mg protein RATIO: 2.2
|
SanverTech., 1999 - Product characterisation form of In Vitro Technologies, SanverTech, 1999.
|
phase I metabolism > CYP3A4 > testosterone 6β-hydroxylation > microsomes |
5800 pmol/min/mg protein RATIO: 1.1
|
SanverTech., 1999 - Product characterisation form of In Vitro Technologies, SanverTech, 1999.
|
phase I metabolism > CYP content > microsomes |
850 pmol CYP/mg protein RATIO: 2.5
|
SanverTech., 1999 - Product characterisation form of In Vitro Technologies, SanverTech, 1999.
|